Study on protective effect of arbutin in yam on acute lung injury and its metabolic regulation mechanism.
10.19540/j.cnki.cjcmm.20250318.701
- Author:
Kai-Li YE
1
;
Meng-Nan ZENG
2
;
Feng-Xiao HAO
1
;
Peng-Li GUO
1
;
Yu-Han ZHANG
1
;
Wei-Sheng FENG
2
;
Xiao-Ke ZHENG
2
Author Information
1. School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China.
2. School of Pharmacy, Henan University of Chinese Medicine Zhengzhou 450046, China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046, China Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province &Ministry of Education of P.R.China, Henan University of Chinese Medicine Zhengzhou 450046, China.
- Publication Type:Journal Article
- Keywords:
TLR4 signaling pathway;
acute lung injury;
arbutin;
inflammatory response;
metabolomics
- MeSH:
Animals;
Acute Lung Injury/chemically induced*;
Mice;
Mice, Inbred BALB C;
Arbutin/administration & dosage*;
Male;
Toll-Like Receptor 4/immunology*;
Apoptosis/drug effects*;
Lung/metabolism*;
Signal Transduction/drug effects*;
Protective Agents/administration & dosage*;
Humans;
Macrophages/immunology*;
Drugs, Chinese Herbal/administration & dosage*
- From:
China Journal of Chinese Materia Medica
2025;50(15):4100-4109
- CountryChina
- Language:Chinese
-
Abstract:
This study investigated the protective effect of arbutin(Arb) in yam on lipopolysaccharide(LPS)-induced acute lung injury(ALI) in a mouse model and revealed its possible mechanism of action by metabolomics technology, providing a theoretical basis for clinical treatment of ALI. SPF BALB/c mice were randomly divided into normal control group, model group, resveratrol(Rv)-positive control group, Arb low-dose(15 mg·kg~(-1)) group, and Arb high-dose(30 mg·kg~(-1)) group. The LPS-induced ALI model was established in all groups except the normal control group. Hematoxylin-eosin(HE) staining, TUNEL staining, and WBP whole-body non-invasive pulmonary function testing were used to evaluate the degree of lung tissue damage and lung function changes. Enzyme-linked immunosorbent assay(ELISA) was used to detect the level of inflammatory factors in lung tissue. Flow cytometry was used to analyze the M1/M2 polarization status of macrophages in lung tissue. Western blot was used to detect the expression levels of the TLR4 signaling pathway and related apoptotic proteins. Liquid chromatograph-mass spectrometer(LC-MS) metabolomics was used to analyze the changes in serum metabolic profile after Arb intervention. The results showed that Arb pretreatment significantly alleviated LPS-induced lung tissue injury, improved lung function, reduced the levels of pro-inflammatory factors(IL-6, TNF-α, IL-18, and IL-1β), and regulated the polarization status of M1/M2 macrophages. In addition, Arb inhibited the activation of the TLR4 signaling pathway, reduced the expression of pro-apoptotic proteins such as Bax, caspase-3, and caspase-9, up-regulated the level of Bcl-2 protein, and inhibited apoptosis of lung cells. Metabolomic analysis showed that Arb significantly improved LPS-induced metabolic abnormalities, mainly involving key pathways such as galactose metabolism, phenylalanine metabolism, and lipid metabolism. In summary, Arb can significantly reduce LPS-induced ALI by regulating the release of inflammatory factors, inhibiting the activation of the TLR4 signaling pathway, improving metabolic disorders, and regulating macrophage polarization, indicating that Arb has potential clinical application value.
